NCT03775265 2026-04-13
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
34 trialsNCT04557059 2026-04-13
PRIMORDIUM
Janssen Pharmaceutica N.V., Belgium
Phase 3 Active not recruiting
NCT05050084 2026-04-08
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Phase 3 Active not recruiting
NCT04513717 2026-04-03
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT03543189 2026-04-01
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT04879940 2026-03-23
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT07477626 2026-03-17
RADVAN
Sun Yat-sen University
Phase 3 Active not recruiting
NCT04422132 2026-02-27
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT06037863 2026-02-23
Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial
Mayo Clinic
Phase NA Active not recruiting
NCT05320406 2026-02-12
REVELUTION
Emory University
Phase 2 Active not recruiting
NCT04997018 2026-01-30
A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03474497 2026-01-29
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Phase 1/2 Active not recruiting
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT04025372 2025-12-15
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT02023463 2025-11-25
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT03987386 2025-11-12
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT04216290 2025-11-12
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01368588 2025-10-28
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT03217747 2025-10-23
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT04319783 2025-08-21
DECREASE
Trans Tasman Radiation Oncology Group
Phase 2 Active not recruiting
NCT05645237 2025-08-19
PRORAD
Erasmus Medical Center
Active not recruiting
NCT03630666 2025-08-17
OLIGOPELVIS2
Institut Cancerologie de l'Ouest
Phase NA Active not recruiting
NCT02177292 2025-07-01
SIB
Medical College of Wisconsin
Phase NA Active not recruiting
NCT00945009 2025-05-31
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Children's Oncology Group
Phase 3 Active not recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT04984343 2025-05-21
FORT
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT04624828 2025-04-24
IOSCAR
Istituto Clinico Humanitas
Phase NA Active not recruiting
NCT04302454 2025-04-04
ADOPT
University Medical Center Groningen
Phase 3 Active not recruiting
NCT00769223 2025-03-20
Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
University of California, San Francisco
Active not recruiting
NCT03763253 2025-02-07
IP2-ATLANTA
Imperial College London
Phase 2 Active not recruiting
NCT00223171 2025-01-27
PCS IV
Université de Sherbrooke
Phase 3 Active not recruiting
NCT01957436 2024-11-12
PEACE1
UNICANCER
Phase 3 Active not recruiting
NCT02799706 2024-11-05
PEGASUS
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT04222634 2023-12-07
MEDCARE
Universitaire Ziekenhuizen KU Leuven
Phase NA Active not recruiting